# US Nontuberculous Mycobacteria Market

> US Nontuberculous Mycobacteria Market Research Report By Class of Drugs (Oral Antibiotics, IV Antibiotics, Anti Nausea, Nebulized Antibiotics) -Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 2.23%
- **2024:** $ 2,020 Million
- **2025:** $ 2,065.05 Million
- **2035:** $ 2,576 Million
- **Key Players:** Thermo Fisher Scientific (US), Merck KGaA (DE), Abbott Laboratories (US), Roche Holding AG (CH), Bio-Rad Laboratories (US), Qiagen N.V. (NL), Hologic, Inc. (US), Becton, Dickinson and Company (US)

**Report ID:** MRFR/HC/51021-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-nontuberculous-mycobacteria-market-52781

---

## Market Summary

## **US Nontuberculous Mycobacteria Market Overview**

As per MRFR analysis, the US Nontuberculous Mycobacteria Market Size was estimated at 1.92 (USD Billion) in 2023.The US Nontuberculous Mycobacteria Market Industry is expected to grow from 2(USD Billion) in 2024 to 3 (USD Billion) by 2035. The US Nontuberculous Mycobacteria Market CAGR (growth rate) is expected to be around 3.755% during the forecast period (2025 - 2035).

**Key US Nontuberculous Mycobacteria Market Trends Highlighted**

The US Nontuberculous Mycobacteria (NTM) market is witnessing significant trends driven by a rise in awareness and diagnosis of NTM infections among healthcare professionals and patients. A greater emphasis on improving public health has led to enhanced diagnostic techniques, allowing for quicker and more accurate identification of these infections. Additionally, the rising prevalence of immunocompromised patients, especially among the aging population, is driving the need for innovative treatment options, which significantly impacts market dynamics in the US.

The Centers for Disease Control and Prevention (CDC) has noted an increase in cases, prompting a greater focus on NTM guidelines and management strategies. Opportunities in this market are emerging as pharmaceutical companies explore novel therapies and diagnostic kits. The rise of personalized medicine is encouraging the development of targeted therapies, which could help address specific patient needs. Collaborations between biotech firms and research institutions in the US are ramping up to conduct clinical trials for new drugs, creating a favorable landscape for advancements in NTM treatment.

Furthermore, the awareness initiatives led by various healthcare organizations are promoting better understanding and management of NTM infections. Recent trends also reflect a growing interest in preventive measures, including improved sanitation practices in healthcare settings. The US has recognized the importance of reducing NTM infection rates through better environmental controls and patient education. This focus on prevention, alongside advancements in diagnostics and treatment options, showcases a comprehensive approach to managing NTM in the healthcare landscape of the United States.

The synergy of these factors is shaping the future of the NTM market in the region, highlighting the dynamic and evolving nature of this sector.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

**US Nontuberculous Mycobacteria Market Drivers**

**Increasing Prevalence of Respiratory Diseases**

The rising prevalence of respiratory disorders such as Chronic Obstructive Pulmonary Disease (COPD) and asthma in the United States is a major driver of the US Nontuberculous Mycobacteria Market Industry. According to the Centers for Disease Control and Prevention (CDC), around 15 million adults in the United States have COPD, while more than 25 million people suffer from asthma. The increase in respiratory difficulties raises the need for diagnostic testing and therapies for Nontuberculous Mycobacteria infections.

Furthermore, the American Lung Association underlines the need for enhanced medicines and increased awareness among healthcare practitioners, hence expanding the market for Nontuberculous Mycobacteria diagnostics and therapies. The need for effective treatment options is expected to drive market expansion considerably in the approaching years.

**Advancements in Diagnostic Technologies**

The continuous advancements in diagnostic technologies significantly contribute to the growth of the US Nontuberculous Mycobacteria Market Industry. Innovations such as Polymerase Chain Reaction (PCR) testing and next-generation sequencing have improved the accuracy and speed of diagnoses related to Nontuberculous Mycobacteria. The National Institutes of Health (NIH) has reported increased research funding for innovative diagnostic methods, which aid in early detection and better patient management.
These technological advancements not only enhance diagnostic capabilities but also foster a competitive edge in the market, thereby driving growth as healthcare providers adopt more sophisticated testing methods.

**Growing Awareness and Education Initiatives**

Growing awareness about Nontuberculous Mycobacteria among both healthcare professionals and the general public serves as a crucial driver of the US Nontuberculous Mycobacteria Market Industry. Organizations such as the Infectious Diseases Society of America (IDSA) have launched campaigns aimed at educating healthcare providers about the impacts of Nontuberculous Mycobacteria and the importance of early identification and treatment. 
Increased education initiatives, including workshops and seminars, are leading to improved recognition of symptoms and conditions related to Nontuberculous Mycobacteria.Consequently, heightened awareness contributes to an uptick in patient consultations, thereby driving demand for diagnostic services and treatment options within the market.

**US Nontuberculous Mycobacteria Market Segment Insights**

**Nontuberculous Mycobacteria Market Class of Drugs Insights  **

The Class of Drugs segment within the US Nontuberculous Mycobacteria Market plays a vital role in addressing the rising concerns of infections caused by nontuberculous mycobacteria. This segment encompasses several treatment options, including Oral Antibiotics, IV Antibiotics, Anti Nausea medications, and Nebulized Antibiotics, each contributing uniquely to patient care. Oral Antibiotics are often the first line of treatment due to their convenience and ease of administration, making them crucial in managing chronic cases and reducing the overall burden on healthcare systems.

IV Antibiotics, on the other hand, are significant for severe infections where immediate and robust intervention is required, showcasing their essential nature in acute care settings. Anti Nausea medications complement antibiotic treatments by helping to manage side effects associated with nontuberculous mycobacteria therapies, thus improving patient compliance and overall treatment efficacy. Nebulized Antibiotics play a critical role in delivering localized treatment for pulmonary infections, allowing for targeted action with minimized systemic exposure, which is particularly important for patients with respiratory complications.

The growing emphasis on personalized medicine and targeted therapies, along with the increasing prevalence of nontuberculous mycobacterial infections in the US, is driving advancements in these drug classes. As healthcare providers and patients alike seek more effective and tolerable treatment options, the Class of Drugs segment is poised to respond swiftly to emerging needs, ensuring optimized care. This segmentation of the US Nontuberculous Mycobacteria Market supports improved patient outcomes, thereby solidifying its importance in the broader context of infectious disease management.

The evolution of treatment paradigms within this segment is also influenced by ongoing Research and Development efforts aimed at enhancing drug efficacy and minimizing adverse reactions. The US healthcare landscape reflects a commitment to addressing the challenges posed by nontuberculous mycobacterial infections, making the Class of Drugs segment crucial for continued progress in the management of these complex conditions.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

**US Nontuberculous Mycobacteria Market Key Players and Competitive Insights**

The competitive landscape of the US Nontuberculous Mycobacteria (NTM) Market reveals a dynamic environment with a growing focus on innovative treatments and diagnostic methods. As awareness of NTM infections has increased, leading to a surge in demand for effective management options, various players are vying for a stronghold in this niche sector. The market consists of several key players who are investing in research and development to enhance their product offerings and expand their market reach.

As the prevalence of NTM infections remains a significant public health concern, competitive strategies largely revolve around advanced therapeutic solutions and the development of state-of-the-art diagnostic tools. The industry's adaptability in response to emerging healthcare needs, alongside regulatory validations, plays a critical role in shaping market dynamics and fostering competition. In examining the strengths of BD within the US Nontuberculous Mycobacteria Market, the company stands out due to its comprehensive portfolio of advanced diagnostic solutions tailored for NTM detection.

Its innovative methodologies and technologies enable rapid and accurate identification of various mycobacterial species, making BD a preferred leader among healthcare providers. The strong foothold of BD is further bolstered by its established distribution channels, which facilitate widespread accessibility to its products across hospitals and laboratories. Moreover, BD's commitment to continuous improvement and customer engagement ensures that it maintains a competitive edge by refining its offerings based on the latest research findings and clinical needs. This responsiveness to the evolving landscape of NTM diagnostics positions BD favorably within this specialized market.

Horizon Discovery has carved out a significant presence in the US Nontuberculous Mycobacteria Market by emphasizing innovative genetic engineering technologies and research products that support NTM studies. Its strengths lie in providing essential tools and services that enable researchers to explore the genomics and biology of NTM species effectively. Horizon Discovery offers a range of genetic models, assay services, and custom solutions that aid in understanding the pathogenesis of NTM infections, thus enhancing therapeutic development efforts. The company maintains a robust market presence through strategic partnerships and collaborations aimed at enhancing research capabilities.

Its emphasis on advancing scientific knowledge, alongside its commitment to quality, positions Horizon Discovery as a valuable contributor to the NTM research and treatment landscape in the US. Additionally, potential mergers and acquisitions conducted by Horizon Discovery may further solidify its market position as it seeks to broaden its technological expertise and expand its service offerings in response to the growing demands of the healthcare sector.

**Key Companies in the US Nontuberculous Mycobacteria Market Include**

**US Nontuberculous Mycobacteria Market Industry Developments**

Recent developments in the US Nontuberculous Mycobacteria Market reflect significant activity among key players. Companies such as BD and Thermo Fisher Scientific continue to innovate in diagnostic technologies, enhancing the detection and management of non-tuberculous mycobacterial infections. In the realm of mergers and acquisitions, BD completed an acquisition of CytomX Therapeutics in September 2022, extending its capabilities in diagnostics. Furthermore, Hologic announced its acquisition of Biotheranostics in November 2022, which bolsters its laboratory services amidst increasing demand for infectious disease testing.

The market's growth is evident, as reports indicate a surge in demand for diagnostic tools, particularly due to heightened awareness following the COVID-19 pandemic. Overall, the focus on Research and Development is driving advancements in microbial detection and treatment options, with companies like Roche, Cepheid, and Qiagen actively participating in the development of innovative solutions. This trend is expected to continue as public health needs evolve, particularly concerning respiratory diseases caused by nontuberculous mycobacteria, contributing to a robust market environment.

**Nontuberculous Mycobacteria Market Segmentation Insights**

## Market Drivers

### Rising Healthcare Expenditure

The increasing healthcare expenditure in the US is a crucial driver for the nontuberculous mycobacteria market. As healthcare budgets expand, there is a greater allocation of resources towards infectious disease management, including nontuberculous mycobacterial infections. This trend is reflected in the growing investments in healthcare infrastructure, research, and development of new therapies. According to the National Health Expenditure Accounts, healthcare spending is projected to grow at an average rate of 5.4% annually, which will likely enhance the availability of diagnostic and therapeutic options in the nontuberculous mycobacteria market. This financial commitment is expected to facilitate advancements in treatment modalities and improve patient outcomes.

### Regulatory Support for New Treatments

Regulatory bodies in the US are providing increased support for the development and approval of new treatments for nontuberculous mycobacterial infections. The Food and Drug Administration (FDA) has streamlined processes for the review of novel therapies, which encourages pharmaceutical companies to invest in research and development. This regulatory environment fosters innovation and expedites the availability of new treatment options in the nontuberculous mycobacteria market. As a result, the market is poised for growth, with new therapies expected to enter the market in the coming years, potentially increasing competition and improving patient access to effective treatments.

### Advancements in Diagnostic Technologies

Technological advancements in diagnostic methods are significantly influencing the nontuberculous mycobacteria market. Innovations such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) have enhanced the accuracy and speed of diagnosing nontuberculous mycobacterial infections. These technologies allow for earlier detection, which is crucial for effective treatment and management. The market for diagnostic tools is projected to grow at a CAGR of approximately 8% over the next five years, driven by the increasing adoption of these advanced methodologies. As healthcare facilities invest in state-of-the-art diagnostic equipment, the nontuberculous mycobacteria market is likely to experience substantial growth, reflecting the critical role of technology in improving patient outcomes.

### Increased Focus on Personalized Medicine

The shift towards personalized medicine is emerging as a significant driver in the nontuberculous mycobacteria market. Tailoring treatment plans based on individual patient profiles enhances therapeutic efficacy and minimizes adverse effects. This trend is particularly relevant in the context of nontuberculous mycobacterial infections, where patient responses to treatment can vary widely. Pharmaceutical companies are increasingly investing in research to develop targeted therapies, which could lead to a more effective management of these infections. The market for personalized medicine is expected to reach $2 trillion by 2025, indicating a robust growth trajectory that will likely benefit the nontuberculous mycobacteria market as well.

### Growing Incidence of Nontuberculous Mycobacterial Infections

The rising incidence of nontuberculous mycobacterial infections in the US is a pivotal driver for the nontuberculous mycobacteria market. Recent data indicates that the prevalence of these infections has increased, particularly among immunocompromised individuals and those with underlying lung conditions. This trend necessitates enhanced diagnostic and therapeutic solutions, thereby propelling market growth. The Centers for Disease Control and Prevention (CDC) has reported a notable rise in cases, which underscores the urgent need for effective treatment options. As healthcare providers become more aware of these infections, the demand for specialized products and services in the nontuberculous mycobacteria market is expected to escalate, potentially leading to a market valuation exceeding $1 billion by 2027.

## Future Outlook

The [Nontuberculous Mycobacteria Market](https://www.marketresearchfuture.com/reports/nontuberculous-mycobacteria-market-16170) is projected to grow at a 2.23% CAGR from 2025 to 2035, driven by increasing awareness and advancements in diagnostic technologies.

**New opportunities:**

- Development of targeted therapies for specific nontuberculous mycobacterial infections.
- Expansion of telehealth services for remote patient monitoring and consultations.
- Investment in advanced diagnostic tools to enhance early detection and treatment efficacy.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic investments.

## Segment Insights

### By Class of Drugs: Oral Antibiotics (Largest) vs. IV Antibiotics (Fastest-Growing)

In the US nontuberculous mycobacteria market, Oral Antibiotics hold the largest market share among the drug classes, representing a significant portion of the total sales. Their established usage and efficacy against various bacterial infections have solidified their position as the go-to choice for many healthcare providers. IV Antibiotics, while less dominant in market share, are gaining traction due to their effective delivery method and rapid action in critical care scenarios, making them an important player in the treatment landscape.

Growth trends indicate that IV Antibiotics are emerging as the fastest-growing segment, driven by an increase in cases requiring urgent medical intervention. The ongoing development of innovative drug formulations and new antibiotic classes is contributing to this growth. Meanwhile, Oral Antibiotics continue to experience steady demand due to their convenience and favorable side effect profile, indicating a stable future for both segments as healthcare practices evolve to meet patient needs.

Oral Antibiotics: Established (Dominant) vs. IV Antibiotics: Innovative (Emerging)

Oral Antibiotics are established as the dominant choice for treating nontuberculous mycobacterial infections, favored for their easy administration and robust clinical evidence supporting their use. They cater to a wide patient demographic, ensuring adherence and consistent treatment outcomes. Conversely, IV Antibiotics are emerging as a critical alternative, particularly for severe infections requiring immediate action. Their innovative formulations are designed to enhance patient recovery, and their usage in hospitals is increasing. The shift towards more aggressive treatment plans and the urgency in tackling more resistant bacterial strains present IV Antibiotics as a vital entity within the market.

## Competitive Benchmarking

The nontuberculous mycobacteria market is currently characterized by a dynamic competitive landscape, driven by increasing awareness of these pathogens and the rising incidence of related diseases. Key players such as Thermo Fisher Scientific (US), Merck KGaA (DE), and Abbott Laboratories (US) are strategically positioned to leverage innovation and technological advancements. For instance, Thermo Fisher Scientific (US) focuses on enhancing its diagnostic capabilities through the development of advanced molecular testing solutions, which appears to be a critical factor in maintaining its competitive edge. Meanwhile, Merck KGaA (DE) emphasizes partnerships with research institutions to foster innovation in drug development, thereby enhancing its operational focus on therapeutic solutions for nontuberculous mycobacterial infections. Collectively, these strategies contribute to a competitive environment that is increasingly reliant on technological innovation and collaborative efforts.In terms of business tactics, companies are increasingly localizing manufacturing to reduce supply chain vulnerabilities and optimize operational efficiency. The market structure is moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of products and services, yet the collective influence of major companies like Roche Holding AG (CH) and Bio-Rad Laboratories (US) shapes market dynamics significantly. Roche Holding AG (CH), for example, has been focusing on expanding its diagnostic portfolio, which may enhance its market share in the nontuberculous mycobacteria segment.

In October  Abbott Laboratories (US) announced the launch of a new rapid diagnostic test specifically designed for nontuberculous mycobacteria. This strategic move is likely to enhance Abbott's position in the market by providing healthcare professionals with faster and more accurate diagnostic tools, thereby addressing a critical need in the clinical setting. The introduction of such innovative solutions may not only improve patient outcomes but also solidify Abbott's reputation as a leader in infectious disease diagnostics.

In September  Hologic, Inc. (US) entered into a collaboration with a leading research university to develop next-generation molecular assays for nontuberculous mycobacteria. This partnership is indicative of Hologic's commitment to advancing diagnostic technologies and reflects a broader trend of collaboration within the industry. By aligning with academic institutions, Hologic may enhance its research capabilities and accelerate the development of cutting-edge diagnostic solutions.

As of November  the competitive trends in the nontuberculous mycobacteria market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and adapt to evolving market demands.

## Recent News & Developments

Recent developments in the US Nontuberculous Mycobacteria Market reflect significant activity among key players. Companies such as BD and Thermo Fisher Scientific continue to innovate in diagnostic technologies, enhancing the detection and management of non-tuberculous mycobacterial infections. In the realm of mergers and acquisitions, BD completed an acquisition of CytomX Therapeutics in September 2022, extending its capabilities in diagnostics. Furthermore, Hologic announced its acquisition of Biotheranostics in November 2022, which bolsters its laboratory services amidst increasing demand for infectious disease testing.

The market's growth is evident, as reports indicate a surge in demand for diagnostic tools, particularly due to heightened awareness following the COVID-19 pandemic. Overall, the focus on Research and Development is driving advancements in microbial detection and treatment options, with companies like Roche, Cepheid, and Qiagen actively participating in the development of innovative solutions. This trend is expected to continue as public health needs evolve, particularly concerning respiratory diseases caused by nontuberculous mycobacteria, contributing to a robust market environment.

## Report Scope

| MARKET SIZE 2024 | 2020.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2065.05(USD Million) |
| MARKET SIZE 2035 | 2576.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.23% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Merck KGaA (DE), Abbott Laboratories (US), Roche Holding AG (CH), Bio-Rad Laboratories (US), Qiagen N.V. (NL), Hologic, Inc. (US), Becton, Dickinson and Company (US) |
| Segments Covered | Class of Drugs |
| Key Market Opportunities | Advancements in diagnostic technologies enhance early detection in the nontuberculous mycobacteria market. |
| Key Market Dynamics | Rising regulatory scrutiny and technological advancements drive innovation in nontuberculous mycobacteria diagnostics and treatment. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US nontuberculous mycobacteria market in 2024?**
A: The market valuation was $2020.0 Million in 2024.

**Q: What is the projected market valuation for the US nontuberculous mycobacteria market in 2035?**
A: The projected valuation for 2035 is $2576.0 Million.

**Q: What is the expected CAGR for the US nontuberculous mycobacteria market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 2.23%.

**Q: Which companies are considered key players in the US nontuberculous mycobacteria market?**
A: Key players include Thermo Fisher Scientific, Merck KGaA, Abbott Laboratories, Roche Holding AG, Bio-Rad Laboratories, Qiagen N.V., Hologic, Inc., and Becton, Dickinson and Company.

**Q: What are the main segments of the US nontuberculous mycobacteria market?**
A: The main segments include Oral Antibiotics, IV Antibiotics, Anti Nausea, and Nebulized Antibiotics.

**Q: What was the valuation of Oral Antibiotics in the US nontuberculous mycobacteria market in 2024?**
A: The valuation of Oral Antibiotics was between $800.0 Million and $1000.0 Million in 2024.

**Q: How much did IV Antibiotics contribute to the US nontuberculous mycobacteria market in 2024?**
A: IV Antibiotics contributed between $600.0 Million and $800.0 Million in 2024.

**Q: What was the market valuation for Anti Nausea drugs in the US nontuberculous mycobacteria market in 2024?**
A: The market valuation for Anti Nausea drugs was between $300.0 Million and $400.0 Million in 2024.

**Q: What is the projected growth trend for Nebulized Antibiotics in the US nontuberculous mycobacteria market?**
A: The valuation for Nebulized Antibiotics is projected to be between $320.0 Million and $376.0 Million in 2024.

**Q: How do the key players influence the US nontuberculous mycobacteria market?**
A: Key players like Abbott Laboratories and Roche Holding AG likely drive innovation and market dynamics through their extensive product portfolios.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-nontuberculous-mycobacteria-market-52781*